Teva Pharmaceutical Industries (TEVA) EPS (Weighted Average and Diluted) (2016 - 2026)
Teva Pharmaceutical Industries (TEVA) recorded quarterly EPS (Weighted Average and Diluted) of $0.31 in Q1 2026, down 24.39% on a QoQ basis from $0.41 in Q4 2025, and up 72.22% year-over-year from $0.18 in Q1 2025.
Teva Pharmaceutical Industries (TEVA) EPS (Weighted Average and Diluted) (2016 - 2026) Analysis & Trends
Teva Pharmaceutical Industries has disclosed EPS (Weighted Average and Diluted) across 11 years of filings, most recently posting $0.31 for Q1 2026.
- Quarterly EPS (Weighted Average and Diluted) rose 72.22% year-over-year to $0.31 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.33 (up 215.65% YoY) and the FY2025 annual result came in at $1.21, up 183.45% from the prior year.
- EPS (Weighted Average and Diluted) eased to $0.31 in Q1 2026, from $0.41 in the prior quarter.
- Over five years, EPS (Weighted Average and Diluted) peaked at $0.41 in Q4 2023 and troughed at -$1.17 in Q4 2022.
- A 5-year average of -$0.16 and a median of -$0.12 in 2024 frame the typical range for EPS (Weighted Average and Diluted).
- Annual changes were most pronounced in 2022 — EPS (Weighted Average and Diluted) sank 1328.57% — and 2025, when it jumped 315.79%.
- Tracing TEVA's EPS (Weighted Average and Diluted) over 5 years: stood at -$1.17 in 2022, then soared by 135.04% to $0.41 in 2023, then sank by 146.34% to -$0.19 in 2024, then soared by 315.79% to $0.41 in 2025, then decreased by 24.39% to $0.31 in 2026.
- Business Quant data shows TEVA's EPS (Weighted Average and Diluted) at $0.31 in Q1 2026, $0.41 in Q4 2025, and $0.37 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 0.31 |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 1.42 |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 5.82 |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 0.02 |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 1.91 |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 0.11 |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -0.40 |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 1.80 |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -0.40 |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn | 0.52 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.31 |
| Dec 31, 2025 | 0.41 |
| Sep 30, 2025 | 0.37 |
| Jun 30, 2025 | 0.24 |
| Mar 31, 2025 | 0.18 |
| Dec 31, 2024 | -0.19 |
| Sep 30, 2024 | -0.39 |
| Jun 30, 2024 | -0.75 |
| Mar 31, 2024 | -0.12 |
| Dec 31, 2023 | 0.41 |
| Sep 30, 2023 | 0.06 |
| Jun 30, 2023 | -0.78 |
| Mar 31, 2023 | -0.20 |
| Dec 31, 2022 | -1.17 |
| Sep 30, 2022 | 0.05 |
| Jun 30, 2022 | -0.23 |
| Mar 31, 2022 | -0.86 |
| Dec 31, 2021 | -0.14 |
| Sep 30, 2021 | 0.26 |
| Jun 30, 2021 | 0.19 |